Document Detail

Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression.
MedLine Citation:
PMID:  12639367     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Perimenopausal depression has been attributed to physiological progressive estrogen decline. Estrogen and derivatives have some mood-enhancing effects, although studies of using estrogen as an antidepressant have had mixed results. The gonadomimetic drug tibolone stimulates estrogen receptors in a tissue-selective fashion, increasing the gonadal activity without causing some of the usual side effects of other estrogen preparations. METHODS: A total of 31 postmenopausal outpatients with a major depressive disorder (MDD) participated in the study. Sixteen received the antidepressant fluoxetine (20 mg/day) plus tibolone (2.5 mg/day), and 15 received the same dose of fluoxetine plus placebo, assigned in a randomized fashion. RESULTS: After 8 weeks of treatment, the two groups had a similar level of improvement in their depressive symptoms. Both treatments were well tolerated, without significant side effects. Pretreatment and posttreatment serum hormonal levels did not predict the final response. CONCLUSIONS: Combining tibolone and fluoxetine did not represent a more robust antidepressant response than fluoxetine alone in postmenopausal women with MDD.
Carlos Berlanga; Danelia Mendieta; Guadalupe Alva; María del Carmen Lara
Related Documents :
6752077 - A clinical trial comparing nomifensine and nortriptyline.
9715427 - Symptom relief with amitriptyline in the irritable bowel syndrome.
8120157 - Fluoxetine for hypochondriacal patients without major depression.
21693167 - Is there tonic immobility in humans? biological evidence from victims of traumatic stress.
9493257 - Clinical trials comparing two treatment policies: which aspects of the treatment polici...
23162477 - Systematic review of parameters of stimulation, clinical trial design characteristics, ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of women's health (2002)     Volume:  12     ISSN:  1540-9996     ISO Abbreviation:  J Womens Health (Larchmt)     Publication Date:    2003 Jan-Feb
Date Detail:
Created Date:  2003-03-17     Completed Date:  2003-06-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101159262     Medline TA:  J Womens Health (Larchmt)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  33-9     Citation Subset:  IM    
National Institute of Psychiatry, Ramón de la Fuente Clinical Research Division, Mexico, DF.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Depressive Disorder / blood,  drug therapy*
Double-Blind Method
Estrogen Receptor Modulators / therapeutic use*
Estrogens / blood
Fluoxetine / therapeutic use*
Middle Aged
Norpregnenes / therapeutic use*
Serotonin Uptake Inhibitors / therapeutic use*
Reg. No./Substance:
0/Estrogen Receptor Modulators; 0/Estrogens; 0/Norpregnenes; 0/Serotonin Uptake Inhibitors; 54910-89-3/Fluoxetine; 5630-53-5/tibolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thyroid hormone use and the risk of hip fracture in women > or = 65 years: a case-control study.
Next Document:  Sexual orientation and variation in physical and mental health status among women.